The epidemiology of invasive fungal infections is changing, with new populations at risk and
the emergence of resistance caused by the selective pressure from increased usage of …

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

Abstract Treatment of invasive fungal infections (IFIs) remains challenging, because of the
limitations of the current antifungal agents (ie, mode of administration, toxicity, and drug-drug …

Background Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1,
with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi …

Mucormycosis are life-threatening fungal infections especially affecting
immunocompromised or diabetic patients. Despite treatment, mortality remains high (from 32 …

Mucormycosis (previously called zygomycosis) is a serious but rare fungal infection caused
by a group of fungi belonging to the order Mucorales. These molds exist throughout the …

Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Mucormycosis (MCR) is an emerging and frequently lethal fungal infection caused by the
Mucorales family, with Rhizopus, Mucor, and Lichtheimia, accounting for> 90% of all cases …

Patients with respiratory viral infections are more likely to develop co-infections leading to
increased fatality. Mucormycosis is an epidemic amidst the COVID-19 pandemic that …